STAT+: Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
SAN FRANCISCO — The failure of a once-promising Alzheimer’s disease medicine from Roche appears to…
Category: STAT+
STAT+: Pharmalittle: Detailed data on Alzheimer’s drug hold up to scrutiny; Horizon in takeover talks with three pharma giants
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues
In the spring of 1981, a geneticist from Indianapolis and a neurologist from Chicago got…
STAT+: Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny
SAN FRANCISCO — A closely watched new treatment for Alzheimer’s disease held up to scrutiny…
STAT+: Horizon Therapeutics in acquisition talks with Amgen, Janssen, and Sanofi
Amgen, Janssen, and Sanofi are in talks to acquire Horizon Therapeutics, the Irish drugmaker confirmed…
STAT+: Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug
Hello, everyone, and how are you today? Gray skies are hovering over the Pharmalot campus…
STAT+: PhRMA, once invincible in Washington, has lost its edge
WASHINGTON — PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics,…
STAT+: ‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period
A hotly contested provision of a federal law designed to speed copycat drugs to market…
STAT+: Pharmalittle: Second clinical trial death may be linked to Eisai-Biogen Alzheimer’s drug; pharma presses the U.K. over ‘out of control’ levy
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Axsome drug reduces agitation in Alzheimer’s patients, data show
A drug developed by Axsome Therapeutics significantly reduced a common side effect of Alzheimer’s disease…
STAT+: Former Merck CEO: Democracy and the drug industry are both in danger
Ken Frazier, the former chief executive of Merck, has been the preeminent pharmaceutical CEO of…
STAT+: Pharmalittle: FDA approves first gene therapy for hemophilia B; pharma’s reputation slips in U.S.
Happy Thanksgiving Eve from STAT reporter Andrew Joseph, filling in for the day. A note…
STAT+: Google Cloud pitches ease and speed to lure health systems wary of tech changes
LAS VEGAS — Google has honed its message for hospital systems wary of moving their…
STAT+: FDA approves a gene therapy for the inherited bleeding disorder hemophilia B
The Food and Drug Administration on Tuesday approved the first gene therapy to treat people…
.jpg)
STAT+: GSK to withdraw blood cancer drug from U.S. market following confirmatory study setback
British pharma giant GSK said Tuesday that it will withdraw its blood cancer drug Blenrep…
STAT+: Pharmalittle: GSK pulls a key blood-cancer drug off the market; Teva picks a new CEO
Good morning, everyone. Damian Garde here filling in for Ed Silverman in the waning days…
STAT+: ‘Digital health is late to the party’: Can telehealth help hospitals mitigate their carbon footprints?
As the world stares down the barrel of climate change, the health care system —…
STAT+: Pharmalittle: Type 1 diabetes drug is priced at $194,000; abortion opponents sue FDA over abortion pill approval
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Northwest Bio study of cancer vaccine still falls short
Northwest Biotherapeutics tried again, but its experimental treatment for brain cancer still falls short. Last…
STAT+: Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases
Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs…
STAT+: Patient groups push federal government to enforce health care price estimates
People don’t receive bills after going to a grocery store or a mechanic’s shop. They…
STAT+: A CEO’s plan to monetize health data rescued from IBM Watson’s wreckage
A company being built from the ashes of IBM’s Watson Health division is launching new…
STAT+: Sales of antibiotics for food-producing animals dropped by nearly half in Europe over the past decade
Amid ongoing concerns over the use of medically important antibiotics given to food-producing livestock and…
STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: Removing barriers to biosimilar adoption in the United States
Biosimilars, a much-lauded approach to reducing drug costs in the United States, are still underused…
STAT+: Nectar bats are ‘wonderful, majestic’ and sugar-obsessed. This researcher wants to know how they stay healthy
Nectar bats may have nature’s biggest sweet tooth. Each night, the creatures scour the jungle…
STAT+: Pharmalittle: Big PBM keeps AbbVie’s Humira on formulary; Lilly CEO says fake tweet means there’s more to do on insulin costs
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Editas, facing another setback, halts development on first clinical CRISPR program
Editas Medicine, one of the small handful of original CRISPR companies, announced Thursday it is…
STAT+: Vertex revolutionized cystic fibrosis treatment. Its executives say that’s just the start
BOSTON — Vertex Pharmaceuticals reshaped the way doctors treat cystic fibrosis, turning what was once…
STAT+: ‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming
NUTLEY, N.J. — A once-in-a-generation medicine was built on more than two decades of regret….
.jpg)
STAT+: Lilly CEO concedes Twitter flap over insulin costs shows there’s ‘more work to do’
After a tweet from a fake corporate account last week claimed Eli Lilly would give…
STAT+: Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone
Top of the morning to you. The middle of the week is upon us and,…
STAT+: ‘If this works, it changes everything’: Altos Labs founders lay out plan to reverse disease
BOSTON — The executives behind Altos Labs would really, really like people to stop saying…
STAT+: Hospital systems Sanford, Fairview plan to create $14 billion Midwest powerhouse
Two not-for-profit Midwest hospital systems are seeking to merge, creating what would be a health…
STAT+: Walmart agrees to pay $3.1 billion in latest settlement stemming from the opioid crisis
In the latest fallout from the opioid crisis that swept the U.S., Walmart agreed to…
STAT+: Amazon jumps into direct-to-consumer telehealth, launching a rival to Ro and Hims
True to its e-commerce expertise, Amazon is jumping into the world of direct-to-consumer telehealth. On…
STAT+: Pharmalittle: Walmart to pay $3.1 billion to settle opioid claims; Indian Covid vaccine underwent troubling approval process
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in Spain have fined a drugmaker $10.6 million for years of “excessive” price…
STAT+: More drugmakers are expanding access in poorer countries, but progress continues to lag overall
For the first time, many of the world’s largest pharmaceutical companies are taking concrete steps…
STAT+: 5 looming questions about the exodus of young life scientists from academia
The unprecedented departure of young life science Ph.D.s and postdocs from academia raises all sorts…
STAT+: Immunogen wins FDA approval for targeted medicine to treat advanced ovarian cancer
The Food and Drug Administration on Monday approved a new treatment for patients with advanced…
STAT+: Despite higher dose, Stoke Therapeutics drug not active enough against childhood epilepsy
Stoke Therapeutics said Monday that a higher dose of its experimental drug for epilepsy reduced…
STAT+: Pharmalittle: Roche Alzheimer’s drug fails in two studies; Indivior bets on addiction market with deal to buy Opiant
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Maven raises $90 million for women’s and family health amid a funding drought
Women’s and family health tech startup Maven Clinic announced Monday it has raised $90 million…
STAT+: After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing
Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster…
STAT+: Google travels far from Silicon Valley to test the power of search tools in health care
Mile Bluff Medical Center is a long way from Silicon Valley. The 40-bed hospital is…
STAT+: With VillageMD investment, Cigna bets on value-based care for a younger, healthier crowd
These days, if you’re an insurer and you’re not buying into the health care provider…
STAT+: Boom and bust: Whose biotech VC assets have grown and shrunk the most?
Money has gushed into the biotech industry over the last couple of years, as the…
STAT+: Roche’s experimental Alzheimer’s treatment fails to slow cognitive decline across two clinical trials
Roche reported negative results Monday from a pair of clinical trials investigating an antibody treatment…
STAT+: Pharmalittle: Lilly says fake Twitter account offered free insulin; AstraZeneca drops plans for Covid shot in the U.S.
And so, another working week will soon draw to a close. Not a moment too…